ストックスクリーナーアプリを入手
8.75
16.11%
1.24
前日終値:
$7.51
開ける：
$7.61
24時間の取引高:
724.78K
Relative Volume:
2.28
時価総額：
$489.26M
収益：
$36.90M
当期純損益:
$-166.28M
株価収益率:
-2.6596
EPS:
-3.29
ネットキャッシュフロー:
$-203.53M
1週間 パフォーマンス:
+11.94%
1か月 パフォーマンス:
-3.96%
6か月 パフォーマンス:
-66.73%
1年 パフォーマンス:
-61.36%
1日の値動き範囲:
$7.61
$8.8968
1週間の範囲:
$7.29
$8.8968
52週間の値動き範囲:
$6.10
$28.67
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
名前
Bicycle Therapeutics Plc Adr
セクター
電話
011441223261503
住所
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
BCYC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
8.78 | 489.26M | 36.90M | -166.28M | -203.53M | -3.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.42 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.18 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
600.02 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.34 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.34 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-08 | 開始されました | Stephens | Equal-Weight |
| 2024-09-06 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-07 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | 開始されました | Cowen | Outperform |
| 2022-07-28 | 開始されました | Barclays | Overweight |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-04-13 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-02-14 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 開始されました | SVB Leerink | Outperform |
| 2021-12-09 | 開始されました | Needham | Buy |
| 2021-09-30 | 開始されました | B. Riley Securities | Buy |
| 2021-04-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-06-12 | 開始されました | Oppenheimer | Outperform |
| 2020-04-17 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-14 | 開始されました | ROTH Capital | Buy |
| 2019-09-11 | アップグレード | Goldman | Neutral → Buy |
| 2019-06-17 | 開始されました | Canaccord Genuity | Buy |
| 2019-06-17 | 開始されました | Goldman | Neutral |
| 2019-06-17 | 開始されました | Jefferies | Buy |
| 2019-06-17 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Bicycle Therapeutics Plc Adr (BCYC) 最新ニュース
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock By Investing.com - Investing.com India
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 By Investing.com - Investing.com South Africa
Bicycle therapeutics COO Alistair Milnes sells $16,850 in stock By Investing.com - Investing.com South Africa
Bicycle Therapeutics chief product officer sells shares worth $5,735 - Investing.com
Bicycle Therapeutics CEO Lee Kevin sells shares worth $43,612 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 - Investing.com
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock - Investing.com
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 By Investing.com - Investing.com UK
Bicycle Therapeutics reshuffles leadership, aims for oncology advances By Investing.com - Investing.com South Africa
Bicycle Therapeutics reshuffles leadership, aims for oncology advances - Investing.com India
Bicycle Therapeutics stock hits 52-week low at $8.98 By Investing.com - Investing.com South Africa
Bicycle Therapeutics’ SWOT analysis: innovative platform drives stock potential - Investing.com India
Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Jefferies cuts Bicycle Therapeutics price target to $42 from $53 By Investing.com - Investing.com South Africa
Bicycle Therapeutics stock holds $33 target, Buy rating at Rodman By Investing.com - Investing.com South Africa
Mizuho maintains Harmony Biosciences $42 target, Outperform rating - Investing.com India
Mizuho maintains Harmony Biosciences $42 target, Outperform rating By Investing.com - Investing.com South Africa
Bicycle Therapeutics stock hits 52-week low at $11.14 By Investing.com - Investing.com South Africa
Bicycle Therapeutics' SWOT analysis: platform potential drives stock outlook - Investing.com India
Bicycle Therapeutics reports promising cancer drug trial results - Investing.com India
Bicycle therapeutics CDO Santiago Arroyo sells shares worth $69,646 - Investing.com India
Bicycle Therapeutics CFO Alethia Young sells shares totaling $19,655 - Investing.com
Bicycle Therapeutics exec sells $30k in shares - Investing.com
Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares By Investing.com - Investing.com South Africa
Bicycle Therapeutics CTO sells shares worth $60,119 By Investing.com - Investing.com South Africa
Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares - Investing.com
Bicycle Therapeutics CEO Lee sells shares worth $172,952 By Investing.com - Investing.com South Africa
Bicycle Therapeutics CEO Lee sells shares worth $172,952 - Investing.com India
Bicycle Therapeutics' SWOT analysis: stock outlook amid clinical trials and cash strength - Investing.com India
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data By Investing.com - Investing.com South Africa
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data - Investing.com
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - Yahoo Finance
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study - Yahoo Finance
Pharmacovigilance and Drug Safety Software Market Size to Reach USD 371.88 Million by 2032, Growing at a 6.76% CAGR – SNS Insider - Yahoo Finance
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study - Yahoo Finance
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potential - Investing.com India
Bicycle Therapeutics' chief accounting officer sells shares worth $157,113 - Investing.com
Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: stock's potential rides on innovative platform - Investing.com India
Bicycle Therapeutics retains stock target and Buy rating on promising data - Investing.com
Bicycle Therapeutics spotlights cancer treatment targets - Investing.com
Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - MSN
BCYC’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Oppenheimer backs Bicycle Therapeutics' BRC platform, reiterates $48 stock PT - Investing.com UK
Bicycle therapeutics CEO sells shares worth over $71k - Investing.com
Bayer Reports Positive Safety Data on Parkinson's Disease Drug - Yahoo Finance
Bicycle Therapeutics Plc Adr (BCYC) 財務データ
収益
当期純利益
現金流量
EPS
Bicycle Therapeutics Plc Adr (BCYC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Skynner Michael | CHIEF TECHNOLOGY OFFICER |
Apr 03 '25 |
Sale |
7.48 |
1,038 |
7,764 |
121,870 |
| Skynner Michael | CHIEF TECHNOLOGY OFFICER |
Apr 02 '25 |
Sale |
8.02 |
814 |
6,528 |
122,908 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER |
Apr 03 '25 |
Sale |
7.48 |
3,432 |
25,671 |
486,265 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER |
Apr 02 '25 |
Sale |
8.02 |
2,237 |
17,941 |
489,697 |
| Milnes Alistair | CHIEF OPERATING OFFICER |
Apr 02 '25 |
Sale |
8.02 |
1,133 |
9,087 |
98,655 |
| Milnes Alistair | CHIEF OPERATING OFFICER |
Apr 03 '25 |
Sale |
7.48 |
1,038 |
7,764 |
97,617 |
| Hannay Michael Charles Ferguso | CHIEF PROD & SUPPLY CHAIN OFF |
Apr 02 '25 |
Sale |
8.02 |
467 |
3,745 |
54,813 |
| Hannay Michael Charles Ferguso | CHIEF PROD & SUPPLY CHAIN OFF |
Apr 03 '25 |
Sale |
7.48 |
266 |
1,990 |
54,547 |
| Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER |
Apr 02 '25 |
Sale |
8.02 |
210 |
1,684 |
31,936 |
| Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER |
Apr 03 '25 |
Sale |
7.48 |
109 |
815 |
31,827 |
1.75%
2.22%
大文字化:
|
ボリューム (24 時間):